The streak had to end eventually. Even Cal Ripken Jr.'s streak came to an end. After 31 consecutive quarters of double-digit sales growth, Stryker
Stryker wasn't alone; the fourth quarter was hard on many medical device makers. Previous high-growers like Intuitive Surgical
Revenue came in just 3.6% higher than the year-ago quarter. Sales of orthopaedic implants grew at 4.2% -- fairly consistent with Johnson & Johnson's
Sales of the normally prolific medical and surgical equipment division grew even slower at just 2.8% year over year. Hospitals just aren't interested in spending money on capital expenses when their own endowments have been hurt by this funky market.
Don't expect those double-digit growth rates to come back anytime soon. Stryker is guiding for a 6% to 9% increase in sales this year. Fortunately management thinks it should be able to squeak more out of the bottom line with estimated earnings per share of $3.12 to $3.22, an increase of 10% to 14% over 2008 after subtracting out restructuring charges.
The days of crazy growth at Stryker are over, but the company is also a lot cheaper, 40% off its 52-week high. Just like the Yankees will one day win the World Series again, I think it's likely that Stryker will get back to starting a new streak fairly soon.
Natus Medical is a Motley Fool Hidden Gems pick. Johnson & Johnson is an Income Investor recommendation. Intuitive Surgical is a Rule Breakers selection. The Fool owns shares of Stryker. Try any of our Foolish newsletters today, free for 30 days.
Fool contributor Brian Orelli, Ph.D., can't wait until pitchers and catchers report for duty next month. He doesn't own shares of any company mentioned in this article. The Fool's disclosure policy has a long track record of being mentioned at the end of Motley Fool articles.
More from The Motley Fool
The Top 3 Dividend Aristocrats to Watch in 2018
Big news in the coming year could send these stocks higher or threaten their payouts.
These 3 Stocks Just Raised Their Dividends
There isn't much time left for companies to get in their last payout hikes of 2017. This trio made it with only weeks to spare.
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
These stocks helped put downward pressure on the market. Find out why.